MedTrace Logo

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

NCT02854748 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-08-09

No results posted yet for this study

Summary

This study is a randomized, open-label, multiple dosing, crossover study to evaluate the drug-drugs interaction between Lobeglitazone and Empagliflozin in healthy male volunteers

Conditions

  • Diabetes Mellitus, Type II

Interventions

DRUG

Empagliflozin 25mg

Empagliflozin 25 mg QD for 5 days

DRUG

Lobeglitazone 0.5mg

Lobeglitazone 0.5mg QD for 5 days

DRUG

Empagliflozin 25mg/Lobeglitazone 0.5mg

Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854748 on ClinicalTrials.gov